Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Colorectal Cancer Drugs Market: By Therapy, By Drug Type, By Distribution Channel and Region Forecast 2019-2030
Colorectal Cancer Drugs Market: By Therapy, By Drug Type, By Distribution Channel and Region Forecast 2019-2030
Colorectal Cancer Drugs Market size was valued at 15.5 billion in 2023 and is expected to reach 23.0 billion by 2030, at a significant CAGR of 8.5% from 2024-2030. Colorectal cancer is also known as bowel cancer. It refers to the abnormal growth of the cells in colon and rectum due to cancer. Colorectal cancer starts either in the colon and rectum. Cancer starts as a polyp in the inner wall of the colon or rectum. These polyps can be benign or malignant. Some of the risk factors that can cause colorectal cancer are lifestyle changes, old age, genetic disorders, family history, and inflammatory bowel disease. Some of the symptoms of colorectal cancer are blood in stool, decrease in appetite, constipation, weight loss, nausea, bloating, and pelvic pain.
Colorectal cancer is the third most common cancer in the world. Huge government initiatives taken by the nations are booming up the growth of the colorectal cancer drugs treatment market globally. Biologics such as Zaltrap (Ziv-Aflibercept), Erbitux (Cetuximab), Avastin (Bevacizumab) are using rapidly for the treatment for colorectal cancer that are used as a targeted therapy and they acts only on the malignant cells. Market players in the market forming strategic alliances and partnerships to increase their market share.
Study Period
2024-2030Base Year
2023CAGR
8.5%Largest Market
Asia-PacificFastest Growing Market
North-America
The market is driven by some of the major factors such as increasing prevalence of colorectal cancer, technological advancements in the cancer therapy, aging population, and raise in consumer awareness about colorectal cancers. However, high costs of screening tests and drugs, lack of knowledge are some of the restraints that are hampering the growth of the global market.
North America expected to grow at significant rate in market owing to the growing incidence of colorectal cancer and widespread awareness about early diagnosis and treatment of colorectal cancer. Asia Pacific region expected to have rapid growth in the market during the forecast period owing to huge population densities and high incidence of colorectal cancer in countries such as India and China.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2024-2030 |
|
Market CAGR |
8.5% |
|
By Therapy |
|
|
By Drug Type |
|
|
By Distribution Channel |
|
|
By Region |
|
Download Free Sample Report
The colorectal cancer drugs market size was valued at US$ 15.5 billion in 2023 and is expected to reach US$ 23.0 billion by 2030, at a CAGR of 8.5% from 2024-2030
The key segments covered in the market are technology, components, application, and end-users.
The market key players are Amgen Inc. (U.S), Bristol-Myers Squibb Company (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Bayer AG (Germany), Merck & Co., Inc. (U.S.), Sanofi (France)
| 1. Executive Summary |
| 2. Global Colorectal Cancer Drugs Market Introduction |
| 2.1.Global Colorectal Cancer Drugs Market - Taxonomy |
| 2.2.Global Colorectal Cancer Drugs Market - Definitions |
| 2.2.1.Therapy |
| 2.2.2.Drug Type |
| 2.2.3.Distribution Channel |
| 2.2.4.Region |
| 3. Global Colorectal Cancer Drugs Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4. Global Colorectal Cancer Drugs Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Colorectal Cancer Drugs Market By Therapy, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Adjuvant Chemotherapy |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Palliative Chemotherapy |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Immuno Therapy |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Neo Adjuvant Chemotherapy |
| 5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 6.Global Colorectal Cancer Drugs Market By Drug Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Capecitabine |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Irinotecan |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Fluorouracil |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Trifluridine/tipiracil |
| 6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Oxaliplatin |
| 6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 6.6. Others |
| 6.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.6.3. Market Opportunity Analysis |
| 7. Global Colorectal Cancer Drugs Market By Distribution Channel, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. Retail Pharmacies |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Hospital Pharmacies |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Online Pharmacies |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 8. Global Colorectal Cancer Drugs Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia Pacific (APAC) |
| 8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Middle East and Africa (MEA) |
| 8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Latin America |
| 8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 9. North America Colorectal Cancer Drugs Market, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 9.1. Therapy Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Adjuvant Chemotherapy |
| 9.1.2.Palliative Chemotherapy |
| 9.1.3.Immuno Therapy |
| 9.1.4.Neo Adjuvant Chemotherapy |
| 9.2. Drug Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Capecitabine |
| 9.2.2.Irinotecan |
| 9.2.3.Fluorouracil |
| 9.2.4.Trifluridine/tipiracil |
| 9.2.5.Oxaliplatin |
| 9.2.6.Others |
| 9.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Retail Pharmacies |
| 9.3.2.Hospital Pharmacies |
| 9.3.3.Online Pharmacies |
| 9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.4.1.United States of America (USA) |
| 9.4.2.Canada |
| 10. Europe Colorectal Cancer Drugs Market, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 10.1. Therapy Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Adjuvant Chemotherapy |
| 10.1.2.Palliative Chemotherapy |
| 10.1.3.Immuno Therapy |
| 10.1.4.Neo Adjuvant Chemotherapy |
| 10.2. Drug Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Capecitabine |
| 10.2.2.Irinotecan |
| 10.2.3.Fluorouracil |
| 10.2.4.Trifluridine/tipiracil |
| 10.2.5.Oxaliplatin |
| 10.2.6.Others |
| 10.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Retail Pharmacies |
| 10.3.2.Hospital Pharmacies |
| 10.3.3.Online Pharmacies |
| 10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Germany |
| 10.4.2.France |
| 10.4.3.Italy |
| 10.4.4.United Kingdom (UK) |
| 10.4.5.Spain |
| 10.4.6.Rest of EU |
| 11. Asia Pacific (APAC) Colorectal Cancer Drugs Market, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 11.1. Therapy Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Adjuvant Chemotherapy |
| 11.1.2.Palliative Chemotherapy |
| 11.1.3.Immuno Therapy |
| 11.1.4.Neo Adjuvant Chemotherapy |
| 11.2. Drug Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Capecitabine |
| 11.2.2.Irinotecan |
| 11.2.3.Fluorouracil |
| 11.2.4.Trifluridine/tipiracil |
| 11.2.5.Oxaliplatin |
| 11.2.6.Others |
| 11.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Retail Pharmacies |
| 11.3.2.Hospital Pharmacies |
| 11.3.3.Online Pharmacies |
| 11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.China |
| 11.4.2.India |
| 11.4.3.Australia and New Zealand (ANZ) |
| 11.4.4.Japan |
| 11.4.5.Rest of APAC |
| 12.Middle East and Africa (MEA) Colorectal Cancer Drugs Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 12.1. Therapy Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Adjuvant Chemotherapy |
| 12.1.2.Palliative Chemotherapy |
| 12.1.3.Immuno Therapy |
| 12.1.4.Neo Adjuvant Chemotherapy |
| 12.2. Drug Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Capecitabine |
| 12.2.2.Irinotecan |
| 12.2.3.Fluorouracil |
| 12.2.4.Trifluridine/tipiracil |
| 12.2.5.Oxaliplatin |
| 12.2.6.Others |
| 12.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Retail Pharmacies |
| 12.3.2.Hospital Pharmacies |
| 12.3.3.Online Pharmacies |
| 12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.GCC Countries |
| 12.4.2.South Africa |
| 12.4.3.Rest of MEA |
| 13. Latin America Colorectal Cancer Drugs Market,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 13.1. Therapy Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Adjuvant Chemotherapy |
| 13.1.2.Palliative Chemotherapy |
| 13.1.3.Immuno Therapy |
| 13.1.4.Neo Adjuvant Chemotherapy |
| 13.2. Drug Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Capecitabine |
| 13.2.2.Irinotecan |
| 13.2.3.Fluorouracil |
| 13.2.4.Trifluridine/tipiracil |
| 13.2.5.Oxaliplatin |
| 13.2.6.Others |
| 13.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Retail Pharmacies |
| 13.3.2.Hospital Pharmacies |
| 13.3.3.Online Pharmacies |
| 13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Brazil |
| 13.4.2.Mexico |
| 13.4.3.Rest of LA |
| 14. Competition Landscape |
| 14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 14.2.1.Amgen Inc. (U.S) |
| 14.2.2.Bristol-Myers Squibb Company (U.S) |
| 14.2.3.F. Hoffmann-La Roche Ltd. (Switzerland) |
| 14.2.4.Bayer AG (Germany) |
| 14.2.5.Merck & Co., Inc. (U.S) |
| 14.2.6.Sanofi (France) |
| 15. Research Methodology |
| 16. Appendix and Abbreviations |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.